AKL > Personalised Medicine

New studies suggests APPA protects against joint damage

Today sees the unveiling of new data at the Osteoarthritis Research Society International (OARSI) Virtual World Congress (April 29 – May 1) indicating investigational oral osteoarthritis (OA) drug APPA can modulate cellular function, reduce inflammation and inhibit bone resorption associated with joint degradation caused by the disease. Read full press release. Biological effect of APPA […]

Read More

Personalised Medicine & Disease Modification in OA

In this article we discuss the challenges in demonstrating disease modification in OA, illustrate this with examples of recently published clinical trials, and describe the current status of APPA, a novel, patented potential Disease Modifying Osteoarthritic Drug (DMOAD).

Read More